Comparing blood pressure management strategies after stroke treatment
Third Enhanced Control of Hypertension and Thrombectomy Stroke Domain Within A Multi-faCtorial, mulTi-arm, Multi-staGe, Randomised, gLOBal Adaptive pLatform Trial for Stroke (ACT-GLOBAL_ENCHANTED3/MT)
This study is testing different ways to manage blood pressure in stroke patients who have had a specific treatment to see which method helps them recover better and reduces risks.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 2000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | The George Institute Academic / other |
| Locations | 2 sites (Sydney, New South Wales and 1 other locations) |
| Trial ID | NCT06352619 on ClinicalTrials.gov |
What this trial studies
This trial aims to evaluate different blood pressure (BP) management strategies in patients who have experienced an acute ischemic stroke and undergone endovascular therapy (EVT). It will randomize up to 2,000 patients with elevated systolic blood pressure (SBP) to receive conservative, moderate, or intensive BP control. The goal is to determine which approach leads to better functional outcomes and minimizes risks such as intracranial hemorrhage. The study is part of a larger adaptive platform trial designed to test multiple treatments for stroke simultaneously.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have undergone EVT for acute ischemic stroke and have sustained high systolic blood pressure of 150 mmHg or higher.
Not a fit: Patients with contraindications to blood pressure lowering treatment will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could identify the optimal blood pressure management strategy that improves recovery outcomes for stroke patients.
How similar studies have performed: Previous studies have shown mixed results regarding blood pressure management in stroke patients, indicating that this approach is still under investigation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥18 years; 2. Use of endovascular therapy (EVT) within 24 hours of symptom onset or last known well according to local guidelines; 3. Sustained high systolic blood pressure ≥150 mmHg (2 readings \<10 mins apart) within 3 hours after completion of EVT. Exclusion Criteria: 1.Any definite contraindications to BP lowering treatment.
Where this trial is running
Sydney, New South Wales and 1 other locations
- The George Institute for Global Health — Sydney, New South Wales, Australia (Recruiting)
- University of Calgary — Calgary, Alberta, Canada (Recruiting)
Study contacts
- Principal investigator: Craig Anderson, PhD — The George Institute
- Study coordinator: Xiaoying Chen, PhD
- Email: xchen@georgeinstitute.org.au
- Phone: +61 2 8052 4549
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.